Salute e Benessere

Brain Navi achieves U.S. FDA approval for neurosurgical robot NaoTrac

We have received FDA 510(k) clearance, which confirms that NaoTrac is substantially equivalent in safety and effectiveness to legally marketed devices in the U.S. This recognition enables us to bring NaoTrac to U.S. hospitals and surgical teams, helping them achieve even higher levels of precision and efficiency in the operating room and save more lives. We have received FDA 510(k) clearance, which confirms that NaoTrac is substantially equivalent in safety and effectiveness to legally…
PR Newswire
17/06/2025

AtomVie Global Radiopharma and TerraPower Isotopes Announce Strategic Supply…

"We are pleased to work with TerraPower Isotopes to ensure a supply of Actinium-225 for our clients. This reinforces our ability to meet the evolving needs of pharmaceutical partners by supporting their programs from development through to commercial supply. Together, we are advancing innovative therapies and improving patients' lives worldwide with high-quality radiopharmaceuticals." said Bruno Paquin, CEO of AtomVie. "We are pleased to work with TerraPower Isotopes to ensure a…
PR Newswire
17/06/2025

One2Treat, the leading company incorporating the patient voice into clinical…

This strategic development supports One2Treat's mission to transform how clinical trials are designed and how treatment value is assessed, anchoring every decision in the perspective of what matters most for patients. This strategic development supports One2Treat's mission to transform how clinical trials are designed and how treatment value is assessed, anchoring every decision in the perspective of what matters most for patients. "This past year has shown that patient-centricity and...
PR Newswire
17/06/2025

Sharjah to Host World Congress for Inclusion 2025 -- First Time in the Middle…

Organized by Sharjah City for Humanitarian Services (SCHS) in collaboration with Inclusion International, the Congress serves as a key forum for exchanging ideas, sharing success stories, and addressing the challenges facing individuals with intellectual disabilities. Organized bySharjahCity for Humanitarian Services (SCHS) in collaboration with Inclusion International, the Congress serves as a key forum for exchanging ideas, sharing success stories, and addressing the challenges facing...
PR Newswire
17/06/2025

Endo Completes International Pharmaceuticals Business Divestiture

About Endo About Endo Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more atwww.endo.com or connect with us onLinkedIn. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements including, but not...
PR Newswire
17/06/2025

Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issueParis, June 17, 2025 -Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches: €750 million fixed-rate notes, due June 2029, bearing interest at an annual rate of 2.625%.€750 million fixed-rate notes, due June 2032, bearing interest at an annual rate of 3.000%. The notes are being issued off the company's Euro Medium Term Note Programme.Sanofi intends to use the net proceeds of...
Nasdaq GlobeNewswire
17/06/2025

Isomorphic Labs appoints Dr. Ben Wolf as Chief Medical Officer and establishes…

As Chief Medical Officer, Dr. Wolf will bring his nearly 20 years of biopharmaceutical experience to Isomorphic Labs, including expertise in precision oncology and advancing novel therapeutic programmes from discovery through to regulatory approval. As Chief Medical Officer, Dr. Wolf will bring his nearly 20 years of biopharmaceutical experience to Isomorphic Labs, including expertise in precision oncology and advancing novel therapeutic programmes from discovery through to regulatory…
PR Newswire
17/06/2025

Lutris Pharma to Present Data from Its Phase 2 Trial of LUT014 Gel for the…

About EGFR Inhibitor-Induced RashEGFR is a receptor on the surface of cells which is expressed in many normal epithelial tissues, including skin. The EGFR signaling pathway is one of the key pathways that regulate growth, survival, proliferation, and differentiation of cells. B-Raf is a protein encoded by the BRAF gene and is a downstream effector component of the EGFR signaling pathway. EGFR has been shown to be over-activated in various human cancers, including colorectal, lung, head and neck…
PR Newswire
17/06/2025

SmartLabs and IWG Announce 10-Year Partnership to Deliver Fully Managed Lab…

Unveiled during the 2025 BIO International Convention in Boston, this first-of-its-kind collaboration will integrate SmartLabs' high-performance lab solutions into IWG's global portfolio of flexible workspace brands—making it significantly easier for life sciences innovators, institutions, and investors to establish R&D capabilities in new and underserved markets around the world. Unveiled during the 2025 BIO International Convention inBoston, this first-of-its-kind collaboration will...
PR Newswire
17/06/2025

European Direct-to-Consumer Genetic Testing Market to Reach USD 3.78 Billion by…

The European DTC genetic testing market is primarily driven by increasing consumer awareness about personalized medicine, growing interest in ancestry and genealogy research, rising prevalence of chronic diseases, and technological advancements in genomic sequencing. The shift towards comprehensive health and wellness testing panels and focus on user-friendly sample collection methods are reshaping the industry, while enhanced data privacy compliance and regulatory frameworks are gaining…
PR Newswire
17/06/2025

LUNESI Officially Launches: Elevating the Standards of Modern Haircare

Rooted in the philosophy of elevated care and sensorial ritual, LUNESI has already caught the attention of fashion icons across Paris, Milan, and New York Fashion Weeks — ahead of its official retail debut. Rooted in the philosophy of elevated care and sensorial ritual, LUNESI has already caught the attention of fashion icons acrossParis,Milan, and New York Fashion Weeks — ahead of its official retail debut. With its refined aesthetic, meticulous formulation and emphasis on...
PR Newswire
17/06/2025

WuXi Biologics Ireland Receives 2025 Operational Excellence in Life Sciences…

Since its inception in 2019, the WuXi Biologics Ireland site has evolved from a greenfield investment into a leading biopharmaceutical facility. The 26-hectare campus now houses three state-of-the-art drug substance manufacturing facilities: MFG6.1 and MFG6.2, with a combined 6,000L perfusion capacity; and MFG7, WuXi Biologics' the largest single-use fed-batch manufacturing site with 48,000L capacity. A significant milestone was achieved in Q4 2024 when all three facilities received GMP…
PR Newswire
17/06/2025

AscellaHealth Wins Business Change and Transformation Excellence Award at the…

DUBLIN and BERWYN, Pa., June17, 2025(GLOBE NEWSWIRE) -- We are proud to announce thatAscellaHealthhas been awarded Gold in the Business Change and Transformation Excellence category at the Industry Eagles Awards 2025,held on 5th June 2025 at The Bentley Hotel, London.The ceremony honoured outstanding achievements across a wide range of sectors, spotlighting those setting benchmarks in innovation, transformation, and excellence. Receiving this recognition among so many...
Nasdaq GlobeNewswire
17/06/2025

Bulletin from the annual general meeting in SciBase Holding AB (publ)

Information regarding the newly elected board members' education, experience, assignments and independence can be found on the Company's website https://investors.scibase.se/sv/bolagsstyrning/bolagsstammor. Information regarding the newly elected board members' education, experience, assignments and independence can be found on the Company's websitehttps://investors.scibase.se/sv/bolagsstyrning/bolagsstammor. For additional information, please contact: Pia Renaudin, CEO Phone: +46 732...
PR Newswire
17/06/2025

Winner of the “Biotherapies and Bioproduction” call for projects under the…

Winner of the “Biotherapies and Bioproduction” call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology Paris, June 17, 2025 –EVerZom, a French biopharmaceutical company pioneering exosome-based therapies for regenerative medicine applications, has announced it has received€3 million in funding as part of the France 2030 plan, through the “Biotherapies and Bioproduction of Innovative...
Nasdaq GlobeNewswire
17/06/2025

COSRX Launches The Ceramide Skin Barrier Moisturiser in the UK: The Viral…

What Are Ceramides - And Why Do They Matter? What Are Ceramides - And Why Do They Matter? Ceramides are natural components of the skin's outermost layer. They act like a protective shield, helping to hold skin cells together and strengthen the skin barrier. When this barrier is strong, the skin is better able to retain moisture and stay protected against irritation, breakouts, dryness, and early signs of ageing. As ceramide levels naturally decrease with age, the skin can become more...
PR Newswire
17/06/2025

Svenska Aerogel delivers 2.6 tons of Quartzene® to a North American manufacturer…

To enable an effective implementation of Quartzene® in large-scale production, the customer has made several operational decisions related to its various production units. The work carried out this spring reflects both the customer's ambition to build a long-term solution and Svenska Aerogel's commitment to supporting an efficient and scalable implementation. To enable an effective implementation of Quartzene® in large-scale production, the customer has made several operational decisions...
PR Newswire
17/06/2025

Corvia Medical closes $55 million funding round to complete confirmatory trial…

The funds will be used to complete the ongoing RESPONDER-HF trial, a double-blinded, randomized, sham-controlled, confirmatory trial of the Corvia® Atrial Shunt currently underway at more than 65 institutions on three continents. The study is expected to generate the final supportive clinical data required for FDA approval of the shunt as a breakthrough treatment for heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF). The funds will be used to complete the…
PR Newswire
17/06/2025

San Raffaele Hospital: World's First Case Study Demonstrates the Effectiveness…

This research builds on a path that began with the first implantation of a spinal cord neurostimulator in 2023, carried out by the neurosurgical team at IRCCS Ospedale San Raffaele led by Professor Pietro Mortini, Head of Neurosurgery at the hospital and Full Professor of Neurosurgery at Vita-Salute San Raffaele University. The path continued with the publication, in Science Translational Medicine in 2025, of the first results from two implanted patients, demonstrating the effectiveness of the…
PR Newswire
17/06/2025

MedHub-AI and Terumo partner to market AI-based FFR in Japan

Traditionally, this procedure involves administering a vasodilatory drug to dilate the blood vessels, followed by the insertion of a guidewire equipped with a pressure sensor into the coronary artery. The sensor measures intravascular pressure changes to determine the FFR value, enabling physicians to assess the severity of arterial blockages. Traditionally, this procedure involves administering a vasodilatory drug to dilate the blood vessels, followed by the insertion of a guidewire equipped...
PR Newswire
17/06/2025

SciBase has signed a Collaboration and License Agreement with Castle Biosciences…

"This collaboration with Castle Biosciences is exciting for SciBase," said Pia Renaudin, CEO of SciBase. "It will accelerate the use of Nevisense within the skin barrier health market. It will rapidly broaden our already existing clinical studies pipeline by increasing the number of studies, ultimately speeding up access to more effective therapies for patients with skin barrier dysfunction. We are also pleased to welcome Castle as a shareholder in SciBase." "This…
PR Newswire
17/06/2025

Implantica announces successful UK RefluxStop™ Users Meeting addressing growing…

Founder and CEO of Implantica, Dr. Peter Forsell, adds, "We sincerely thank and appreciate the world-leading healthcare policy advisory body, UK NICE, for their extensive and thorough review and announcement of the final positive recommendations for the RefluxStop™ procedure. Given how rampant GERD is in the UK, with up to 20% of the adult population struggling with the persistent discomfort and pain from the disease, the NICE recommendations for RefluxStop procedure couldn't be more…
PR Newswire
17/06/2025

Invitation to presentation of Essity's interim report for quarter 2, 2025

Contact information for conference call with the possibility to ask questions:UK: +44 (0) 33 0551 02 00 USA: +1 786 697 35 01SWE: +46 (0)8 505 204 24Please call in well in advance of the start of the presentation. Indicate: "Essity". Contact information for conference call with the possibility to ask questions: UK: +44 (0) 33 0551 02 00 USA : +1 786 697 35 01 SWE: +46 (0)8 505 204 24 Please call in well in advance of the start of the presentation. Indicate…
PR Newswire
17/06/2025

Johnson & Johnson Launches New TECNIS Odyssey Next-Generation Intraocular Lens…

TECNIS Odyssey IOL enables surgeons to deliver consistent and reliable patient outcomes.∫7,15 TECNIS Odyssey IOL enables surgeons to deliver consistent and reliable patient outcomes.∫7,15 This content is intended for Healthcare Professionals only, not for the general public. JACKSONVILLE, Fla. , June 17, 2025 /PRNewswire/ -- Johnson & Johnson, §a global leader in eye health, announced today that it is expanding its portfolio of presbyopia-correcting intraocular lenses...
PR Newswire
17/06/2025
Altri  Comunicati